Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2017.06.003
Abstract: Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting… read more here.
Keywords: non del; del; del mds; myelodysplastic syndromes ... See more keywords
MMP9 Inhibition Rescues the Erythroid Defect in RPS14-Deficient Del(5q) MDS Models
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117508
Abstract: The del(5q) myelodysplastic syndrome (MDS) is a unique subtype of MDS characterized by an interstitial deletion of the long arm of chromosome 5 with macrocytic anemia, normal to increased platelet count, and hypoloblated megakaryocytes. Although… read more here.
Keywords: mds; treatment; rps14 deficient; del mds ... See more keywords
Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006061
Abstract: Key Points Csnk1a1 haploinsufficient hematopoietic stem cells outcompete other key genes in del(5q) MDS in direct competitive transplantation. Chronic inflammatory stress increases the competitive advantage of Csnk1a1 haploinsufficient hematopoietic stem cells. read more here.
Keywords: del mds; barcoding systematically; genes del; genetic barcoding ... See more keywords